The CR rates of DLBCL patients with Ki67 ≥85% and Ki67 <85% were 69.6% and 81.6%, and the 2-year PFS rates were 44.3% and 74.1%, respectively. This evidence concerns the gene MKI67 and diffuse large B-cell lymphoma.